Issued 2026-08-13 at $9.07 · now $9.08 (2026-08-13, +0.1% since)
Based on its own history, a month from the 2026-08-13 close, SLDB has typically landed between $6.16 and $13.79 — a range of −32.1% to +52.0% from the issuance price $9.07.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,122 overlapping 1 month windows · 2018-01-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($9.07) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where SLDB has typically landed a month from the 2026-08-13 close of $9.07 — the range is history, not a prediction.
- now $9.08 (+0.1%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $8.62 (-5.0%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $6.93–$10.3
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $6.16–$13.79
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2019-01-09 | −76.7% | −76.9% | +0.9% |
| 2019-01-08 | −76.5% | −76.5% | +2.4% |
| 2018-02-26 | −76.0% | −76.0% | +10.7% |
| 3 best | |||
| 2023-11-14 | +143.7% | +0.0% | +143.7% |
| 2020-12-07 | +141.6% | +0.0% | +141.6% |
| 2023-11-22 | +135.9% | +0.0% | +135.9% |
2,122 overlapping windows · 2018-01-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-10-15 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Microdystrophin Gene Transfer Study in Adolescents and Children With DMD (source, as of 2026-08-14)
- 2027-05-06 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) (source, as of 2026-08-14)
- January 2029 — Trial primary completion: Phase 3 primary completion: A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.